Kelly Cowen, MD
Family Medicine · Rockville, MDNPI 1225033731
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Bristol Myers Squibb at 57.1% of the total. Reporting peaked in 2024 at $14,293 and has fallen 98.9% since, to $163 in 2025. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $159.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$472
- Johnson & Johnson$207
- Novo Nordisk$171
- plus $1K from 19 others
What the payments were for
- Consulting fees$5,36031%
- Travel & lodging$9,76557%
- Food & beverage$2,12112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 9 | $9,843 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,284 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| AbbVie(2 entities) | 23 | $472 |
| Johnson & Johnson(3 entities) | 4 | $207 |
| Novo Nordisk | 10 | $171 |
| Pfizer | 10 | $167 |
| Merck | 15 | $164 |
| Exactech, Inc. | 1 | $114 |
| Amgen | 5 | $100 |
| GSK | 5 | $94 |
| AstraZeneca | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Boehringer Ingelheim | 2 | $46 |
| Abbott | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Orasure Technologies Inc. | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Lifescan, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Gilead | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- XARELTO$137
- EQUINOXE$114
How this compares
$17,246 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $69,024 |
| OzempicSemaglutide | 38 | $63,966 |
| JanuviaSitagliptin Phosphate | 26 | $42,635 |
| JardianceEmpagliflozin | 29 | $36,336 |
| EliquisApixaban | 13 | $21,901 |
| XareltoRivaroxaban | 16 | $16,552 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $11,973 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,970 |
| SynthroidLevothyroxine Sodium | 117 | $7,955 |
| Rosuvastatin Calcium | 261 | $7,128 |
| Atorvastatin Calcium | 333 | $4,551 |
| Lansoprazole | 15 | $3,661 |
| Pregabalin | 25 | $2,722 |
| Levothyroxine Sodium | 191 | $2,413 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 22 | $2,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $171 | $63,96638 claims |
| MerckJanuvia | $164 | $42,63526 claims |
| Boehringer IngelheimJardiance | $46 | $36,33629 claims |
| PfizerEliquis, Paxlovid | $167 | $23,33130 claims |
| Johnson & JohnsonXarelto | $207 | $16,55216 claims |
| GSKBreo Ellipta | $94 | $11,97019 claims |
| AbbVieSynthroid | $472 | $7,955117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Rockville
- Alec AndersRockville$38K
- Manthan MiraniRockville$14K
- Hon Yuen WongRockville$10K
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.